Plasma NfL is associated with mild cognitive decline in patients with diabetes

Patients with diabetes are at a higher risk for cognitive decline. Thus, biomarkers that can provide early and simple detection of cognitive decline are required. Neurofilament light chain (NfL) is a cytoskeletal protein that constitutes neural axons. Plasma NfL levels are elevated when neurodegeneration occurs. Here, we investigated whether plasma NfL levels were associated with cognitive decline in patients with type 2 diabetes.

[1]  Timothy J. Hohman,et al.  Neurofilament relates to white matter microstructure in older adults , 2018, Neurobiology of Aging.

[2]  C. Jack,et al.  Plasma and CSF neurofilament light , 2019, Neurology.

[3]  C. Enzinger,et al.  Serum neurofilament light levels in normal aging and their association with morphologic brain changes , 2020, Nature Communications.

[4]  K. Blennow,et al.  Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype , 2007, European journal of neurology.

[5]  P. Snyder,et al.  Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis , 2016, Alzheimer's & dementia.

[6]  Timothy J. Hohman,et al.  Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities , 2018, Neurobiology of Aging.

[7]  G. Biessels,et al.  Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications , 2018, Nature Reviews Endocrinology.

[8]  L. Fratiglioni,et al.  Cognitive support at episodic encoding and retrieval: similar patterns of utilization in community-based samples of Alzheimer's disease and vascular dementia patients. , 1999, Journal of clinical and experimental neuropsychology.

[9]  David T. Jones,et al.  Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults , 2019, Neurology.

[10]  Sterling C. Johnson,et al.  Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[11]  G. Piñol-Ripoll,et al.  Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. , 2014, Neurologia.

[12]  D. Balota,et al.  Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. , 2020, Journal of Alzheimer's disease : JAD.

[13]  D. Bennett,et al.  Diabetes is related to cerebral infarction but not to AD pathology in older persons , 2006, Neurology.

[14]  M. Yassuda,et al.  Relations between attachment styles, ageism and quality of life in late life , 2010, International Psychogeriatrics.

[15]  Y. Xiong,et al.  An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer's disease. , 2017, Diabetes research and clinical practice.

[16]  A. Bhansali,et al.  Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies , 2013, Journal of diabetes investigation.

[17]  L. Fratiglioni,et al.  Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer's disease , 2004, Journal of the International Neuropsychological Society.

[18]  Nick C Fox,et al.  Serum neurofilament light in familial Alzheimer disease A marker of early neurodegeneration , 2022 .

[19]  L. Bäckman,et al.  Cognitive Functioning in Alzheimer's Disease and Vascular Dementia: Further Evidence for Similar Patterns of Deficits , 2002, Journal of clinical and experimental neuropsychology.

[20]  Philip S. Insel,et al.  Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease , 2016, EMBO molecular medicine.

[21]  V. Srikanth,et al.  Type 2 diabetes mellitus and biomarkers of neurodegeneration , 2015, Neurology.

[22]  A. Arauz,et al.  Prospective Study of Single and Multiple Lacunar Infarcts Using Magnetic Resonance Imaging: Risk Factors, Recurrence, and Outcome in 175 Consecutive Cases , 2003, Stroke.

[23]  K. Blennow,et al.  Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[24]  M. A. Viergever,et al.  Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus , 2007, Diabetologia.

[25]  Prashanthi Vemuri,et al.  Age, vascular health, and Alzheimer disease biomarkers in an elderly sample , 2017, Annals of neurology.

[26]  G. Capasso,et al.  Mechanisms of cognitive dysfunction in CKD , 2020, Nature Reviews Nephrology.

[27]  Brian A. Gordon,et al.  Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease , 2018, Neurology.

[28]  L. Grinberg,et al.  Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration , 2014, Annals of neurology.

[29]  K. Blennow,et al.  CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults , 2017, Neurobiology of Aging.

[30]  Alzheimer's Disease Neuroimaging Initiative.  Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .

[31]  M. Carnethon,et al.  Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. , 2020, The lancet. Diabetes & endocrinology.

[32]  F. Schmitt,et al.  Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology , 2016, Alzheimer's & Dementia.

[33]  Shunichiro Shinagawa,et al.  Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale‐Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease , 2013, Psychiatry and clinical neurosciences.

[34]  E. Mori,et al.  Everyday Memory Impairment of Patients with Mild Cognitive Impairment , 2005, Dementia and Geriatric Cognitive Disorders.

[35]  H. Yao,et al.  Hippocampal atrophy and memory dysfunction associated with physical inactivity in community‐dwelling elderly subjects: The Sefuri study , 2016, Brain and behavior.

[36]  Ludwig Kappos,et al.  Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.

[37]  Nick C Fox,et al.  Serum neurofilament light in familial Alzheimer disease , 2017, Neurology.

[38]  Keith A. Johnson,et al.  The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals , 2018, Annals of neurology.

[39]  Henrik Zetterberg,et al.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.

[40]  E. Wressle,et al.  Validation of the Neurobehavioral Cognitive Status Examination and the Rivermead Behavioural Memory Test in investigations of dementia , 2012, Scandinavian journal of occupational therapy.

[41]  Gabriel A. Devenyi,et al.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease , 2020, Molecular Psychiatry.

[42]  Á. Chamorro,et al.  A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction , 2002, Neuroscience Letters.

[43]  Vilmundur Gudnason,et al.  Diabetes, markers of brain pathology and cognitive function , 2014, Annals of neurology.